
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.
Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 29, 12, 1, 76, 42 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 8 and 1 molecules, respectively.
Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.
Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 29, 12, 1, 76, 42 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 8 and 1 molecules, respectively.
Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
514 Pages
- Introduction
- Global Markets Direct Report Coverage
- Cystic Fibrosis – Overview
- Cystic Fibrosis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cystic Fibrosis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cystic Fibrosis – Companies Involved in Therapeutics Development
- 4D Molecular Therapeutics Inc
- AbbVie Inc
- Abeona Therapeutics Inc
- Aceragen Inc
- Aeon Respire Inc
- Agile Sciences Inc
- AiCuris Anti-infective Cures AG
- Airbase Breathing Co LLC
- Airway Therapeutics Inc
- AlgiPharma AS
- Antabio SAS
- Arch Biopartners Inc
- Arcturus Therapeutics Holdings Inc
- Armata Pharmaceuticals Inc
- Arrevus Inc
- Arrowhead Pharmaceuticals Inc
- Astria Therapeutics Inc
- Atlantic Healthcare Plc
- Avidin Biotechnology Ltd
- Biofilm Pharma
- Biolytx Pharmaceuticals Corp
- BiomX Inc
- Boehringer Ingelheim International GmbH
- Boston Pharmaceuticals Inc
- Branca Bunus Ltd
- Breathe Easy Therapeutics Ltd
- BridgeBio Pharma Inc
- Calista Therapeutics Inc
- Calithera Biosciences Inc
- Carbon Biosciences Inc
- Chiesi Farmaceutici SpA
- Cilian AG
- Clarametyx Biosciences Inc
- ContraFect Corp
- Copernicus Therapeutics Inc
- CRISPR Therapeutics AG
- CSA Biotechnologies LLC
- Cyclacel Pharmaceuticals Inc
- Cyclenium Pharma Inc
- Destiny Pharma Plc
- DiscoveryBiomed Inc
- Editas Medicine Inc
- Eloxx Pharmaceuticals Inc
- EmphyCorp Inc
- enGene Inc
- Enterprise Therapeutics Ltd
- Entrinsic Bioscience Inc
- Evaxion Biotech ApS
- Evotec SE
- F. Hoffmann-La Roche Ltd
- Feldan Therapeutics Inc
- Felix Biotechnology Inc
- Helperby Therapeutics Group Ltd
- Hunterian Medicine LLC
- Icagen Inc
- Insmed Inc
- Invion Ltd
- Kamada Pharmaceuticals
- Kither Biotech Srl
- Krystal Biotech Inc
- Lakewood-Amedex Inc
- Lamellar Biomedical Ltd
- Laurent Pharmaceuticals Inc
- Loxegen Pty Ltd
- MannKind Corp
- Mariposa Health Ltd
- Microbion Corp
- Mucokinetica Ltd
- Nabriva Therapeutics Plc
- Nanogenics Ltd
- Neupharma Srl
- New Amsterdam Sciences Inc
- Novabiotics Ltd
- Omnispirant Ltd
- Orphomed Inc
- OrPro Therapeutics Inc
- Oryn Therapeutics
- Parion Sciences Inc
- Peptilogics Inc
- Peter Biotherapeutics Inc
- Pharmaero ApS
- PhaseBio Pharmaceuticals Inc
- Progenra Inc
- Prolong Pharmaceuticals LLC
- PureIMS BV
- Pylum Biosciences Inc
- RAGE Biotech Pty Ltd
- Rare Partners Srl
- Reata Pharmaceuticals Inc
- Recode Therapeutics Inc
- Renovion Inc
- Respirion Pharmaceuticals Pty Ltd
- Riptide Bioscience Inc
- RS BioTherapeutics Inc
- Saliogen Therapeutics Inc
- San Rocco Therapeutics LLC
- Sanofi
- Santhera Pharmaceuticals Holding AG
- Sarcomed AB
- SciBac Inc
- SciClone Pharmaceuticals Holdings Ltd
- Shape Therapeutics Inc
- Silurian Pharmaceuticals Inc
- Sionna Therapeutics Inc
- SOLA Biosciences LLC
- SolAeroMed Inc
- Specific Biologics Inc
- Spexis AG
- Spirovant Sciences Inc
- SpliSense Ltd
- Synedgen Inc
- Synovo GmbH
- Synspira Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Tavanta Therapeutics Inc
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Thirty Respiratory Ltd
- Translate Bio Inc
- Vast Therapeutics Inc
- Vectura Group Plc
- Vera Therapeutics Inc
- Verona Pharma Plc
- Vertex Pharmaceuticals Inc
- VGSK Technologies Inc
- Vironika LLC
- Yumanity Therapeutics Inc
- Zambon Co SpA
- Zata Pharmaceuticals Inc
- Cystic Fibrosis – Drug Profiles
- (ammonium chloride + citric acid + sodium citrate) – Drug Profile
- (elexacaftor + ivacaftor + tezacaftor) + ivacaftor – Drug Profile
- (ethylenediaminetetraacetic acid + sodium nitrite) – Drug Profile
- (ivacaftor + lumacaftor) – Drug Profile
- (ivacaftor + tezacaftor + bamocaftor potassium) – Drug Profile
- (ivacaftor + tezacaftor) + ivacaftor – Drug Profile
- 4D-710 – Drug Profile
- ABBV-191 – Drug Profile
- ABO-401 – Drug Profile
- ACF-516 – Drug Profile
- ADDITIONAL SMALL MOLECULES 1 – Drug Profile
- AGL-503 – Drug Profile
- alidornase alfa – Drug Profile
- alpha-1 proteinase inhibitor (human) second generation – Drug Profile
- ANT-3273 – Drug Profile
- APPA-02 – Drug Profile
- ARCT-032 – Drug Profile
- ARO-ENaC2 – Drug Profile
- ARV-1907 – Drug Profile
- ascorbic acid – Drug Profile
- AT-010 – Drug Profile
- AvR-2V10 – Drug Profile
- BBP-321 – Drug Profile
- BFP-002 – Drug Profile
- BFP-102 – Drug Profile
- BI-1323495 – Drug Profile
- BI-3720931 – Drug Profile
- BIOC-51 – Drug Profile
- BOS-857 – Drug Profile
- BP-002 – Drug Profile
- BrB-102 – Drug Profile
- brensocatib – Drug Profile
- brevenal – Drug Profile
- BX-004 – Drug Profile
- Calcaftor – Drug Profile
- CAT-5571 – Drug Profile
- CB-280 – Drug Profile
- CF-370 – Drug Profile
- CGT-001 – Drug Profile
- CHF-6333 – Drug Profile
- CMTX-101 – Drug Profile
- colistimethate sodium – Drug Profile
- CSA-13 – Drug Profile
- cysteamine – Drug Profile
- Cystic Fibrosis – Drug Profile
- dirocaftor – Drug Profile
- dornase alfa – Drug Profile
- Drug for Cystic Fibrosis – Drug Profile
- Drug to Inhibit SLPI for Asthma and Cystic Fibrosis – Drug Profile
- Drugs for Cystic Fibrosis – Drug Profile
- Drugs to Activate CFTR for Cystic Fibrosis – Drug Profile
- EBX-001 – Drug Profile
- ECP-104 – Drug Profile
- EG-i08 – Drug Profile
- ELX-02 – Drug Profile
- ensifentrine – Drug Profile
- ETD-001 – Drug Profile
- ETD-002 – Drug Profile
- ETX-001 – Drug Profile
- EVXB-2 – Drug Profile
- fenretinide – Drug Profile
- FTX-003 – Drug Profile
- fusidic acid – Drug Profile
- galicaftor – Drug Profile
- Gene Therapy for Cystic Fibrosis – Drug Profile
- Gene Therapy for Cystic Fibrosis and Retinitis Pigmentosa – Drug Profile
- Gene Therapy to Activate CFTR for Cystic Fibrosis – Drug Profile
- heparin sodium – Drug Profile
- HY-006 – Drug Profile
- ICL4 Additional Candidates – Drug Profile
- ivacaftor – Drug Profile
- KB-407 – Drug Profile
- KIT-2014 – Drug Profile
- lefamulin acetate – Drug Profile
- LMS-611 – Drug Profile
- lonodelestat – Drug Profile
- MG-277 – Drug Profile
- MRT-5005 – Drug Profile
- Mul-1867 – Drug Profile
- murepavadin – Drug Profile
- N-115 – Drug Profile
- nadolol – Drug Profile
- nafamostat mesylate – Drug Profile
- NAS-415 – Drug Profile
- navocaftor – Drug Profile
- NBD1 Additional Candidates – Drug Profile
- nesolicaftor – Drug Profile
- niclosamide – Drug Profile
- NU-8 – Drug Profile
- OligoG – Drug Profile
- Oligonucleotide to Activate CFTR for Cystic Fibrosis – Drug Profile
- Oligonucleotides for Cystic Fibrosis – Drug Profile
- Oligonucleotides to Activate CFTR for Cystic Fibrosis – Drug Profile
- Optate – Drug Profile
- ORP-100S – Drug Profile
- ORP-110 – Drug Profile
- OTP-602 – Drug Profile
- P-2114 – Drug Profile
- P-2176 – Drug Profile
- Pemziviptadil – Drug Profile
- PLG-0301 – Drug Profile
- posenacaftor – Drug Profile
- pravibismane – Drug Profile
- Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis, Hospital Acquired Pneumonia and Diabetic Foot Infection – Drug Profile
- PTINC-733 – Drug Profile
- RBR-042 – Drug Profile
- Recombinant Enzyme to Inhibit DNA for Cystic Fibrosis – Drug Profile
- renzapride – Drug Profile
- RP-557 – Drug Profile
- RSBT-001 – Drug Profile
- RTX-0001 – Drug Profile
- RVT-801 – Drug Profile
- S-1226 – Drug Profile
- S-1229 – Drug Profile
- Sanguinate – Drug Profile
- SBI-001 – Drug Profile
- SCB-203 – Drug Profile
- seliciclib – Drug Profile
- SHP-111 – Drug Profile
- SHP-636 – Drug Profile
- SION-109 – Drug Profile
- SION-638 – Drug Profile
- Small Molecule for Cystic Fibrosis – Drug Profile
- Small Molecule to Activate CFTR for Cystic Fibrosis – Drug Profile
- Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease – Drug Profile
- Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD – Drug Profile
- Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis – Drug Profile
- Small Molecules for Cystic Fibrosis – Drug Profile
- Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis – Drug Profile
- Small Molecules for Respiratory Diseases – Drug Profile
- Small Molecules to Activate CFTR for Cystic Fibrosis – Drug Profile
- Small Molecules to Block SCNN1 for Cystic Fibrosis – Drug Profile
- Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis – Drug Profile
- Small Molecules to Inhibit Penicillin Binding Protein for Gram-Negative Bacterial Infections and Cystic Fibrosis – Drug Profile
- SNSP-113 – Drug Profile
- sodium calcium edetate + tobramycin – Drug Profile
- sodium nitrite – Drug Profile
- SOL-512 – Drug Profile
- SPIRO-2101 – Drug Profile
- SPIRO-2102 – Drug Profile
- SPIRO-2110 – Drug Profile
- SPL-16 – Drug Profile
- SPL-232 – Drug Profile
- SPL-24N – Drug Profile
- SPL-5A – Drug Profile
- SPL-5B – Drug Profile
- SPL-8423 – Drug Profile
- SRI-41315 – Drug Profile
- SYD-0073 – Drug Profile
- SYGN-303 – Drug Profile
- TA-270 – Drug Profile
- TAVT-135 – Drug Profile
- teicoplanin – Drug Profile
- thymalfasin – Drug Profile
- TMD1 Candidates – Drug Profile
- tobramycin – Drug Profile
- tobramycin + triclosan – Drug Profile
- trimethylangelicin – Drug Profile
- VS-009 – Drug Profile
- VX-121 + deutivacaftor + tezacaftor – Drug Profile
- VX-551 – Drug Profile
- VXc-0522 – Drug Profile
- VXc-522 – Drug Profile
- XF-70 – Drug Profile
- YPT-01 – Drug Profile
- zelpultide alfa – Drug Profile
- Cystic Fibrosis – Dormant Projects
- Cystic Fibrosis – Discontinued Products
- Cystic Fibrosis – Product Development Milestones
- Featured News & Press Releases
- Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound
- Jul 07, 2022: Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for public reimbursement of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children With cystic fibrosis ages 6 and older
- Jun 11, 2022: Vertex to present data demonstrating significant benefits of long-term and early treatment With CFTR modulators at the European Cystic Fibrosis Conference
- May 18, 2022: Recode therapeutics presents new preclinical data from mRNA-based program for cystic fibrosis at the ATS 2022 International Conference
- Apr 21, 2022: Health Canada approves Vertex’s Trikafta for cystic fibrosis in children
- Apr 18, 2022: ContraFect announces multiple presentations of new data demonstrating the potential of its Direct Lytic Agent CF-370 to address antimicrobial resistance at the 32nd Annual ECCMID Meeting
- Apr 12, 2022: Entrinsic Bioscience steps closer to amino acid formulation as therapy for cystic fibrosis
- Apr 11, 2022: Nabriva Therapeutics announces first patient enrolled in phase 1 trial of XENLETA (lefamulin) in adult patients with cystic fibrosis
- Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine
- Mar 29, 2022: Eloxx Pharmaceuticals announces therapeutic development Award from Cystic Fibrosis Foundation
- Mar 26, 2022: Vertex announces reimbursement agreement in Australia for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients With cystic fibrosis ages 12 years and older with at least one F508del mutation in the CFTR gene
- Mar 25, 2022: Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H Mutation in the CFTR Gene
- Jan 12, 2022: EC approves Vertex’s combination therapy for cystic fibrosis in children
- Jan 05, 2022: SpliSense announces FDA and EMA grant Orphan Drug Designation to SPL84-23-1 for the treatment of cystic fibrosis
- Jan 05, 2022: Peptilogics receives award from the Cystic Fibrosis Foundation to investigate PLG0301 as potential dual-acting treatments for lung infections associated with cystic fibrosis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Cystic Fibrosis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
- Table 9: Number of Products under Development by Universities/Institutes, 2022
- Table 10: Products under Development by Companies, 2022
- Table 11: Products under Development by Companies, 2022 (Contd..1)
- Table 12: Products under Development by Companies, 2022 (Contd..2)
- Table 13: Products under Development by Companies, 2022 (Contd..3)
- Table 14: Products under Development by Companies, 2022 (Contd..4)
- Table 15: Products under Development by Companies, 2022 (Contd..5)
- Table 16: Products under Development by Companies, 2022 (Contd..6)
- Table 17: Products under Development by Companies, 2022 (Contd..7)
- Table 18: Products under Development by Companies, 2022 (Contd..8)
- Table 19: Products under Development by Companies, 2022 (Contd..9)
- Table 20: Products under Development by Universities/Institutes, 2022
- Table 21: Number of Products by Stage and Target, 2022
- Table 22: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 23: Number of Products by Stage and Mechanism of Action, 2022
- Table 24: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 25: Number of Products by Stage and Route of Administration, 2022
- Table 26: Number of Products by Stage and Molecule Type, 2022
- Table 27: Cystic Fibrosis – Pipeline by 4D Molecular Therapeutics Inc, 2022
- Table 28: Cystic Fibrosis – Pipeline by AbbVie Inc, 2022
- Table 29: Cystic Fibrosis – Pipeline by Abeona Therapeutics Inc, 2022
- Table 30: Cystic Fibrosis – Pipeline by Aceragen Inc, 2022
- Table 31: Cystic Fibrosis – Pipeline by Aeon Respire Inc, 2022
- Table 32: Cystic Fibrosis – Pipeline by Agile Sciences Inc, 2022
- Table 33: Cystic Fibrosis – Pipeline by AiCuris Anti-infective Cures AG, 2022
- Table 34: Cystic Fibrosis – Pipeline by Airbase Breathing Co LLC, 2022
- Table 35: Cystic Fibrosis – Pipeline by Airway Therapeutics Inc, 2022
- Table 36: Cystic Fibrosis – Pipeline by AlgiPharma AS, 2022
- Table 37: Cystic Fibrosis – Pipeline by Antabio SAS, 2022
- Table 38: Cystic Fibrosis – Pipeline by Arch Biopartners Inc, 2022
- Table 39: Cystic Fibrosis – Pipeline by Arcturus Therapeutics Holdings Inc, 2022
- Table 40: Cystic Fibrosis – Pipeline by Armata Pharmaceuticals Inc, 2022
- Table 41: Cystic Fibrosis – Pipeline by Arrevus Inc, 2022
- Table 42: Cystic Fibrosis – Pipeline by Arrowhead Pharmaceuticals Inc, 2022
- Table 43: Cystic Fibrosis – Pipeline by Astria Therapeutics Inc, 2022
- Table 44: Cystic Fibrosis – Pipeline by Atlantic Healthcare Plc, 2022
- Table 45: Cystic Fibrosis – Pipeline by Avidin Biotechnology Ltd, 2022
- Table 46: Cystic Fibrosis – Pipeline by Biofilm Pharma, 2022
- Table 47: Cystic Fibrosis – Pipeline by Biolytx Pharmaceuticals Corp, 2022
- Table 48: Cystic Fibrosis – Pipeline by BiomX Inc, 2022
- Table 49: Cystic Fibrosis – Pipeline by Boehringer Ingelheim International GmbH, 2022
- Table 50: Cystic Fibrosis – Pipeline by Boston Pharmaceuticals Inc, 2022
- Table 51: Cystic Fibrosis – Pipeline by Branca Bunus Ltd, 2022
- Table 52: Cystic Fibrosis – Pipeline by Breathe Easy Therapeutics Ltd, 2022
- Table 53: Cystic Fibrosis – Pipeline by BridgeBio Pharma Inc, 2022
- Table 54: Cystic Fibrosis – Pipeline by Calista Therapeutics Inc, 2022
- Table 55: Cystic Fibrosis – Pipeline by Calithera Biosciences Inc, 2022
- Table 56: Cystic Fibrosis – Pipeline by Carbon Biosciences Inc, 2022
- Table 57: Cystic Fibrosis – Pipeline by Chiesi Farmaceutici SpA, 2022
- Table 58: Cystic Fibrosis – Pipeline by Cilian AG, 2022
- Table 59: Cystic Fibrosis – Pipeline by Clarametyx Biosciences Inc, 2022
- Table 60: Cystic Fibrosis – Pipeline by ContraFect Corp, 2022
- Table 61: Cystic Fibrosis – Pipeline by Copernicus Therapeutics Inc, 2022
- Table 62: Cystic Fibrosis – Pipeline by CRISPR Therapeutics AG, 2022
- Table 63: Cystic Fibrosis – Pipeline by CSA Biotechnologies LLC, 2022
- Table 64: Cystic Fibrosis – Pipeline by Cyclacel Pharmaceuticals Inc, 2022
- Table 65: Cystic Fibrosis – Pipeline by Cyclenium Pharma Inc, 2022
- Table 66: Cystic Fibrosis – Pipeline by Destiny Pharma Plc, 2022
- Table 67: Cystic Fibrosis – Pipeline by DiscoveryBiomed Inc, 2022
- Table 68: Cystic Fibrosis – Pipeline by Editas Medicine Inc, 2022
- Table 69: Cystic Fibrosis – Pipeline by Eloxx Pharmaceuticals Inc, 2022
- Table 70: Cystic Fibrosis – Pipeline by EmphyCorp Inc, 2022
- Table 71: Cystic Fibrosis – Pipeline by enGene Inc, 2022
- Table 72: Cystic Fibrosis – Pipeline by Enterprise Therapeutics Ltd, 2022
- Table 73: Cystic Fibrosis – Pipeline by Entrinsic Bioscience Inc, 2022
- Table 74: Cystic Fibrosis – Pipeline by Evaxion Biotech ApS, 2022
- Table 75: Cystic Fibrosis – Pipeline by Evotec SE, 2022
- Table 76: Cystic Fibrosis – Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 77: Cystic Fibrosis – Pipeline by Feldan Therapeutics Inc, 2022
- Table 78: Cystic Fibrosis – Pipeline by Felix Biotechnology Inc, 2022
- Table 79: Cystic Fibrosis – Pipeline by Helperby Therapeutics Group Ltd, 2022
- Table 80: Cystic Fibrosis – Pipeline by Hunterian Medicine LLC, 2022
- Table 81: Cystic Fibrosis – Pipeline by Icagen Inc, 2022
- Table 82: Cystic Fibrosis – Pipeline by Insmed Inc, 2022
- Table 83: Cystic Fibrosis – Pipeline by Invion Ltd, 2022
- Table 84: Cystic Fibrosis – Pipeline by Kamada Pharmaceuticals, 2022
- Table 85: Cystic Fibrosis – Pipeline by Kither Biotech Srl, 2022
- Table 86: Cystic Fibrosis – Pipeline by Krystal Biotech Inc, 2022
- Table 87: Cystic Fibrosis – Pipeline by Lakewood-Amedex Inc, 2022
- Table 88: Cystic Fibrosis – Pipeline by Lamellar Biomedical Ltd, 2022
- Table 89: Cystic Fibrosis – Pipeline by Laurent Pharmaceuticals Inc, 2022
- Table 90: Cystic Fibrosis – Pipeline by Loxegen Pty Ltd, 2022
- Table 91: Cystic Fibrosis – Pipeline by MannKind Corp, 2022
- Table 92: Cystic Fibrosis – Pipeline by Mariposa Health Ltd, 2022
- Table 93: Cystic Fibrosis – Pipeline by Microbion Corp, 2022
- Table 94: Cystic Fibrosis – Pipeline by Mucokinetica Ltd, 2022
- Table 95: Cystic Fibrosis – Pipeline by Nabriva Therapeutics Plc, 2022
- Table 96: Cystic Fibrosis – Pipeline by Nanogenics Ltd, 2022
- Table 97: Cystic Fibrosis – Pipeline by Neupharma Srl, 2022
- Table 98: Cystic Fibrosis – Pipeline by New Amsterdam Sciences Inc, 2022
- Table 99: Cystic Fibrosis – Pipeline by Novabiotics Ltd, 2022
- Table 100: Cystic Fibrosis – Pipeline by Omnispirant Ltd, 2022
- Table 101: Cystic Fibrosis – Pipeline by Orphomed Inc, 2022
- Table 102: Cystic Fibrosis – Pipeline by OrPro Therapeutics Inc, 2022
- Table 103: Cystic Fibrosis – Pipeline by Oryn Therapeutics, 2022
- Table 104: Cystic Fibrosis – Pipeline by Parion Sciences Inc, 2022
- Table 105: Cystic Fibrosis – Pipeline by Peptilogics Inc, 2022
- Table 106: Cystic Fibrosis – Pipeline by Peter Biotherapeutics Inc, 2022
- Table 107: Cystic Fibrosis – Pipeline by Pharmaero ApS, 2022
- Table 108: Cystic Fibrosis – Pipeline by PhaseBio Pharmaceuticals Inc, 2022
- Table 109: Cystic Fibrosis – Pipeline by Progenra Inc, 2022
- Table 110: Cystic Fibrosis – Pipeline by Prolong Pharmaceuticals LLC, 2022
- Table 111: Cystic Fibrosis – Pipeline by PureIMS BV, 2022
- Table 112: Cystic Fibrosis – Pipeline by Pylum Biosciences Inc, 2022
- Table 113: Cystic Fibrosis – Pipeline by RAGE Biotech Pty Ltd, 2022
- Table 114: Cystic Fibrosis – Pipeline by Rare Partners Srl, 2022
- Table 115: Cystic Fibrosis – Pipeline by Reata Pharmaceuticals Inc, 2022
- Table 116: Cystic Fibrosis – Pipeline by Recode Therapeutics Inc, 2022
- Table 117: Cystic Fibrosis – Pipeline by Renovion Inc, 2022
- Table 118: Cystic Fibrosis – Pipeline by Respirion Pharmaceuticals Pty Ltd, 2022
- Table 119: Cystic Fibrosis – Pipeline by Riptide Bioscience Inc, 2022
- Table 120: Cystic Fibrosis – Pipeline by RS BioTherapeutics Inc, 2022
- Table 121: Cystic Fibrosis – Pipeline by Saliogen Therapeutics Inc, 2022
- Table 122: Cystic Fibrosis – Pipeline by San Rocco Therapeutics LLC, 2022
- Table 123: Cystic Fibrosis – Pipeline by Sanofi, 2022
- Table 124: Cystic Fibrosis – Pipeline by Santhera Pharmaceuticals Holding AG, 2022
- Table 125: Cystic Fibrosis – Pipeline by Sarcomed AB, 2022
- Table 126: Cystic Fibrosis – Pipeline by SciBac Inc, 2022
- Table 127: Cystic Fibrosis – Pipeline by SciClone Pharmaceuticals Holdings Ltd, 2022
- Table 128: Cystic Fibrosis – Pipeline by Shape Therapeutics Inc, 2022
- Table 129: Cystic Fibrosis – Pipeline by Silurian Pharmaceuticals Inc, 2022
- Table 130: Cystic Fibrosis – Pipeline by Sionna Therapeutics Inc, 2022
- Table 131: Cystic Fibrosis – Pipeline by SOLA Biosciences LLC, 2022
- Table 132: Cystic Fibrosis – Pipeline by SolAeroMed Inc, 2022
- Table 133: Cystic Fibrosis – Pipeline by Specific Biologics Inc, 2022
- Table 134: Cystic Fibrosis – Pipeline by Spexis AG, 2022
- Table 135: Cystic Fibrosis – Pipeline by Spirovant Sciences Inc, 2022
- Table 136: Cystic Fibrosis – Pipeline by SpliSense Ltd, 2022
- Table 137: Cystic Fibrosis – Pipeline by Synedgen Inc, 2022
- Table 138: Cystic Fibrosis – Pipeline by Synovo GmbH, 2022
- Table 139: Cystic Fibrosis – Pipeline by Synspira Therapeutics Inc, 2022
- Table 140: Cystic Fibrosis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 141: Cystic Fibrosis – Pipeline by Tavanta Therapeutics Inc, 2022
- Table 142: Cystic Fibrosis – Pipeline by TGV-Inhalonix Inc, 2022
- Table 143: Cystic Fibrosis – Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
- Table 144: Cystic Fibrosis – Pipeline by Thirty Respiratory Ltd, 2022
- Table 145: Cystic Fibrosis – Pipeline by Translate Bio Inc, 2022
- Table 146: Cystic Fibrosis – Pipeline by Vast Therapeutics Inc, 2022
- Table 147: Cystic Fibrosis – Pipeline by Vectura Group Plc, 2022
- Table 148: Cystic Fibrosis – Pipeline by Vera Therapeutics Inc, 2022
- Table 149: Cystic Fibrosis – Pipeline by Verona Pharma Plc, 2022
- Table 150: Cystic Fibrosis – Pipeline by Vertex Pharmaceuticals Inc, 2022
- Table 151: Cystic Fibrosis – Pipeline by VGSK Technologies Inc, 2022
- Table 152: Cystic Fibrosis – Pipeline by Vironika LLC, 2022
- Table 153: Cystic Fibrosis – Pipeline by Yumanity Therapeutics Inc, 2022
- Table 154: Cystic Fibrosis – Pipeline by Zambon Co SpA, 2022
- Table 155: Cystic Fibrosis – Pipeline by Zata Pharmaceuticals Inc, 2022
- Table 156: Cystic Fibrosis – Dormant Projects, 2022
- Table 157: Cystic Fibrosis – Dormant Projects, 2022 (Contd..1)
- Table 158: Cystic Fibrosis – Dormant Projects, 2022 (Contd..2)
- Table 159: Cystic Fibrosis – Dormant Projects, 2022 (Contd..3)
- Table 160: Cystic Fibrosis – Dormant Projects, 2022 (Contd..4)
- Table 161: Cystic Fibrosis – Dormant Projects, 2022 (Contd..5)
- Table 162: Cystic Fibrosis – Dormant Projects, 2022 (Contd..6)
- Table 163: Cystic Fibrosis – Dormant Projects, 2022 (Contd..7)
- Table 164: Cystic Fibrosis – Dormant Projects, 2022 (Contd..8)
- Table 165: Cystic Fibrosis – Dormant Projects, 2022 (Contd..9)
- Table 166: Cystic Fibrosis – Dormant Projects, 2022 (Contd..10)
- Table 167: Cystic Fibrosis – Discontinued Products, 2022
- Table 168: Cystic Fibrosis – Discontinued Products, 2022 (Contd..1)
- List of Figures
- Figure 1: Number of Products under Development for Cystic Fibrosis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.